NEW YORK CITY, NY / ACCESS Newswire / January 25, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ:NKTR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Nektar and certain of its officers and/or directors […]

NEW YORK CITY, NY / ACCESS Newswire / January 25, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ:CORT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Corcept and certain of its officers and/or

NEW YORK CITY, NY / ACCESS Newswire / January 25, 2026 / Pomerantz LLP is investigating claims on behalf of investors of New Era Energy & Digital, Inc. ("New Era" or the "Company") (NASDAQ:NUAI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether New Era and

NEW YORK CITY, NY / ACCESS Newswire / January 25, 2026 / Pomerantz LLP is investigating claims on behalf of investors of BigBear.ai Holdings, Inc. ("BigBear" or the "Company") (NYSE:BBAI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether BigBear and certain of its officers and/or

NEW YORK CITY, NY / ACCESS Newswire / January 25, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Phoenix Education Partners, Inc. ("Phoenix" or the "Company") (NYSE:PXED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Phoenix and certain of its officers

NEW YORK CITY, NY / ACCESS Newswire / January 25, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. ("Organogenesis" or the "Company") (NASDAQ:ORGO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Organogenesis and certain of its officers and/or

NEW YORK CITY, NY / ACCESS Newswire / January 25, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Galectin Therapeutics Inc. ("Galectin" or the "Company") (NASDAQ:GALT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Galectin and certain of its officers and/or

NEW YORK CITY, NY / ACCESS Newswire / January 25, 2026 / Pomerantz LLP is investigating claims on behalf of investors of RxSight, Inc. ("RxSight" or the "Company") (NASDAQ:RXST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether RxSight and certain of its officers and/or directors

NEW YORK CITY, NY / ACCESS Newswire / January 25, 2026 / Pomerantz LLP is investigating claims on behalf of investors of PDD Holdings Inc. ("PDD" or the "Company") (NASDAQ:PDD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether PDD and certain of its officers and/or

NEW YORK CITY, NY / ACCESS Newswire / January 25, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Nutanix, Inc. ("Nutanix" or the "Company") (NASDAQ:NTNX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Nutanix and certain of its officers and/or directors